HAE in the News

CSL Behring announces that HAEGARDA® is now available in all of Canada for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients. (April 6, 2021)

Takeda Canada announced that negotions with the pan Canadian Pharmaceutical Alliance (pCPA) are complete and HAE patients in Canada are now one step closer to having access to TAKHZYRO^® (lanadelumab injection). 

TAKHZYRO® (lanadelumab injection) receives positive recommendation from CADTH’s Canadian Drug Expert Committee (CDEC) for the routine prevention of hereditary angioedema (HAE) attacks (Nov 22, 2019)

Health Canada has authorized TAKHZYRO (TM) (lanadelumab injection), a first-of-its-kind monoclonal antibody treatment for the prevention of hereditary angioedema (HAE) attacks (September 20, 2018)

Berinert® Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients (August 9, 2017)

New and Convenient Vial Size of CSL Behring’s Berinert® approved by Health Canada for the Treatment of Hereditary Angioedema (May 15, 2015)

Firazyr®: First Subcutaneous Treatment for Acute Attacks of Rare and Serious Swelling Disorder Now Available in Canada (July 17, 2014)

Health Canada Approves New Drug Submission for Cinryze™ (C1 inhibitor [human]) (October 22, 2012)

CSL Behring Receives Canadian Notice of Compliance for Berinert® (June 2, 2010)